Lauri M. Burroughs, MD

Seattle Cancer Care Alliance
Associate Professor, Department of Pediatrics
University of Washington School of Medicine
Associate Professor, Clinical Research Division
Fred Hutchinson Cancer Research Center
Director, Non-Malignant Transplant Program
Seattle Cancer Care Alliance/Seattle Children's/Fred Hutch
Medical Oncology
“Families give me a wonderful gift when they teach me a lesson that I can use to help the next patient.”
— Dr. Burroughs
Why do you specialize in treating and researching non-malignant blood disorders?

I started my career thinking I was going to go into pediatric oncology, but I ended up being drawn to patients with non-malignant (non-cancerous) blood disorders. These diseases can profoundly compromise a child’s quality of life and shorten their lifespan. It’s an area of medicine that historically hasn’t been given as much attention as blood cancers like leukemias, so there’s a huge need for more research and better treatment options. As I got to know children with these disorders, it was obvious that they deserved a better life. Ever since then, I’ve been motivated to try to address the many challenges these patients and their families are up against.  

What experiences have informed your research and approach to care?

Every year, I attend a free summer camp for children and their families who are dealing with a rare type of blood disorder. I am one of many experts who come to talk about the disease and the new therapies that are coming along, but I feel that I learn just as much as the parents and children who attend. I hear about the struggles these families face and what it means for them to live day in and day out with this disorder. Their stories not only inform the way I take care of patients back home but also inspire me to research ways to improve their quality of life. 

Provider background

Specialty: Medical Oncology

Non-malignant blood disorders

I specialize in caring for children with non-malignant blood disorders, such as sickle cell disease and bone marrow failure syndromes. I also serve as the director of the Non-Malignant Transplant Program for SCCA, Seattle Children’s and Fred Hutchinson Cancer Research Center. In this role, I review and help develop the clinical practice standards for patients with non-malignant blood disorders. 

My research is focused on developing safer, more effective bone marrow transplant procedures for children with these diseases. Prior to receiving a transplant, patients undergo a process called conditioning where they receive high doses of chemotherapy or radiation. Although conditioning prepares the body for an influx of transplanted blood cells, it can have toxic side effects. I am conducting national clinical trials to evaluate the use of gentler pre-transplant conditioning regimens. 

Diseases treated

Education, experience and certifications
Undergraduate Degree
University of Wisconsin
Medical Degree
University of Wisconsin School of Medicine and Public Health, Madison
Indiana University School of Medicine, Pediatrics
University of Washington School of Medicine, Pediatric Hematology-Oncology
Board Certification
Pediatric Hematology-Oncology, 2009, American Board of Pediatrics; General Pediatrics, 2001, American Board of Pediatrics
Internship, Indiana University School of Medicine


Clinical trials

We make promising new treatments available to you through studies called clinical trials led by SCCA doctors. Many of these trials at SCCA have led to FDA-approved treatments and have improved standards of care globally. Together, you and your doctor can decide if a study is right for you.

Study ID:
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders
Complete title
Allogeneic hematopoietic cell transplantation for patients with non-malignant disorders using Treosulfan, Fludarabine, and Thiotepa
Study ID:
Conditioning SCID Infants Diagnosed Early (CSIDE)
Complete title
A randomized trial of low versus moderate exposure busulfan for infants with severe combined immunodeficiency (SCID) receiving TCRαβ+/CD19+ depleted transplantation
Study ID:
NCT01659606     Pediatric trial
Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
Complete title
Radiation and Alkylator-free conditioning for allogeneic hematopoietic cell transplantation for bone marrow failure due to dyskeratosis congenita/telomere disease


Many of our SCCA physicians conduct ongoing research to improve standards of patient care. Their work is evaluated by other physicians and selected for publication to the United States National Library of Medicine, the largest medical library in the world. See scientific papers this SCCA provider has written.

Your care team

At SCCA, you receive care from a team of providers with extensive experience in your disease. Your team includes doctors, a team coordinator, a registered nurse, an advanced practice provider and others, based on your needs. You also have access to experts like nutritionists, social workers, acupuncturists, psychiatrists and more who specialize in supporting people with cancer or blood disorders.
Registered nurse (RN)
Registered nurse (RN)
Your nurse manages your care alongside your physician and assists with care procedures and treatments.
Team coordinator (TC)
Team coordinator (TC)
Your team coordinator works closely with you and your physician and serves as your scheduler.


SCCA accepts most national private health insurance plans as well as Medicare. We also accept Medicaid for people from Washington, Alaska, Montana and Idaho. We are working to ensure that everyone, no matter what their financial situation, has access to the care they need.

For providers